Top

Current Hepatology Reports

Published in:

Open Access 13-07-2023 | Hypertension

Non-invasive Assessment of Clinically Significant Portal Hypertension

Authors: Maximilian Joseph Brol, Juliana Gödiker, Frank Erhard Uschner, Michael Praktiknjo, Jonel Trebicka

Published in: Current Hepatology Reports | Issue 3/2023

Abstract

Purpose of Review

Clinically significant portal hypertension (CSPH) is a serious clinical condition causing decompensation and potentially fatal complications especially in the presence of advanced liver disease. This article aims to critically review the current literature on non-invasive assessment of CSPH.

Recent Findings

The Baveno VII consensus encouraged non-invasive assessment of CSPH to identify patients at risk and avoid unnecessary screening endoscopies. Novel machine learning and omics-based laboratory scores have been introduced, which can be combined with liver stiffness measurement (LSM). Spleen stiffness measurement (SSM) is an increasingly used novel elastography modality. Elastography and cross-sectional imaging methods have reached similar predictive power, while the accuracy of non-invasive tests can only be improved when used sequentially.

Summary

In this review, we provide a detailed discussion of advantages and limitations of non-invasive assessment of CSPH, highlighting their diagnostic accuracy, reproducibility, and feasibility in clinical practice.

Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–61. https://doi.org/10.1056/NEJMoa044456.CrossRefPubMed

de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Abraldes JG, Albillos A, Baiges A, Bajaj J, Bañares R, et al. Baveno VII – renewing consensus in portal hypertension. J Hepatol. 2022;76:959–74. https://doi.org/10.1016/j.jhep.2021.12.022.CrossRefPubMed

Banini BA, Patel S, Yu JW, Kang L, Bailey C, Strife BJ, Siddiqui MS, Patel V, Matherly SC, Lee H, et al. Derivation and validation of a model to predict clinically significant portal hypertension using transient elastography and FIB-4. J Clin Gastroenterol. 2023;57:189–97. https://doi.org/10.1097/MCG.0000000000001664.CrossRefPubMed

Rabiee A, Deng Y, Ciarleglio M, Chan JL, Pons M, Genesca J, Garcia-Tsao G. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: validation of ANTICIPATE Models and development of a lab-based model. Hepatol Commun. 2022;6:3324–34. https://doi.org/10.1002/hep4.2091.CrossRefPubMedPubMedCentral

Stefanescu H, Rusu C, Lupsor-Platon M, Nicoara Farcau O, Fischer P, Grigoras C, Horhat A, Stancu O, Ardelean A, Tantau M, et al. Liver stiffness assessed by ultrasound shear wave elastography from general electric accurately predicts clinically significant portal hypertension in patients with advanced chronic liver disease. Ultraschall Med. 2020;41:526–33. https://doi.org/10.1055/a-0965-0745.CrossRefPubMed

Kani̇ HT, Kekli̇kkiran Ç, Ergenç İ, Yilmaz Y (2022) Evaluation of spleen stiffness in healthy population: a vibration-controlled transient elastography study. J Health Sci Med 5:689–692https://doi.org/10.32322/jhsm.1074776

Karagiannakis DS, Voulgaris T, Koureta E, Chloupi E, Papatheodoridis GV, Vlachogiannakos J. Role of spleen stiffness measurement by 2D-shear wave elastography in ruling out the presence of high-risk varices in cirrhotic patients. Dig Dis Sci. 2019;64:2653–60. https://doi.org/10.1007/s10620-019-05616-4.CrossRefPubMed

Trebicka J, Gu W, de Ledinghen V, Aubé C, Krag A, Praktiknjo M, Castera L, Dumortier J, Bauer DJM, Friedrich-Rust M, et al. Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease. Gut. 2022;71:402–14. https://doi.org/10.1136/gutjnl-2020-323419.CrossRefPubMed

Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy. JHEP Rep. 2021;3:100316. https://doi.org/10.1016/j.jhepr.2021.100316.CrossRefPubMedPubMedCentral

10.

Glisic T, StojkovicLalosevic M, Milovanovic T, Rankovic I, Stojanovic M, Toplicanin A, Aleksic M, Milivojevic V, MartinovNestorov J, Lolic I, et al. Diagnostic value of non-invasive scoring systems in the prediction of esophageal varices in patients with liver cirrhosis-single center experience. Medicina (Kaunas). 2022;58:158. https://doi.org/10.3390/medicina58020158.CrossRefPubMed

11.

Reiniš J, Petrenko O, Simbrunner B, Hofer BS, Schepis F, Scoppettuolo M, Saltini D, Indulti F, Guasconi T, Albillos A, et al. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis. J Hepatol. 2023;78:390–400. https://doi.org/10.1016/j.jhep.2022.09.012.CrossRefPubMed

12.

Benz F, Bogen A, Praktiknjo M, Jansen C, Meyer C, Wree A, Demir M, Loosen S, Vucur M, Schierwagen R, et al. Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis. PLoS One. 2020;15:e0231701. https://doi.org/10.1371/journal.pone.0231701.CrossRefPubMedPubMedCentral

13.

Berres M-L, Asmacher S, Lehmann J, Jansen C, Görtzen J, Klein S, Meyer C, Strunk HM, Fimmers R, Tacke F, et al. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. J Hepatol. 2015;62:332–9. https://doi.org/10.1016/j.jhep.2014.09.032.CrossRefPubMed

14.

Berres M-L, Lehmann J, Jansen C, Görtzen J, Meyer C, Thomas D, Zimmermann HW, Kroy D, Schumacher F, Strassburg CP, et al. Chemokine (C-X-C Motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Liver Int. 2016;36:386–94. https://doi.org/10.1111/liv.12922.CrossRefPubMed

15.

Lehmann JM, Claus K, Jansen C, Pohlmann A, Schierwagen R, Meyer C, Thomas D, Manekeller S, Claria J, Strassburg CP, et al. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality. Liver Int. 2018;38:875–84. https://doi.org/10.1111/liv.13610.CrossRefPubMed

16.

Praktiknjo M, Monteiro S, Grandt J, Kimer N, Madsen JL, Werge MP, William P, Brol MJ, Turco L, Schierwagen R, et al. Cardiodynamic state is associated with systemic inflammation and fatal acute-on-chronic liver failure. Liver Int. 2020;40:1457–66. https://doi.org/10.1111/liv.14433.CrossRefPubMed

17.

Leeming DJ, Karsdal MA, Byrjalsen I, Bendtsen F, Trebicka J, Nielsen MJ, Christiansen C, Møller S, Krag A. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol Ther. 2013;38:1086–96. https://doi.org/10.1111/apt.12484.CrossRefPubMedPubMedCentral

18.

Leeming DJ, Veidal SS, Karsdal MA, Nielsen MJ, Trebicka J, Busk T, Bendtsen F, Krag A, Møller S. Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis. Scand J Gastroenterol. 2015;50:584–92. https://doi.org/10.3109/00365521.2014.996590.CrossRefPubMed

19.

Nielsen MJ, Lehmann J, Leeming DJ, Schierwagen R, Klein S, Jansen C, Strassburg CP, Bendtsen F, Møller S, Sauerbruch T, et al. Circulating elastin fragments are not affected by hepatic, renal and hemodynamic changes, but reflect survival in cirrhosis with TIPS. Dig Dis Sci. 2015;60:3456–64. https://doi.org/10.1007/s10620-015-3783-9.CrossRefPubMed

20.

Jansen C, Leeming DJ, Mandorfer M, Byrjalsen I, Schierwagen R, Schwabl P, Karsdal MA, Anadol E, Strassburg CP, Rockstroh J, et al. PRO-C3-levels in patients with HIV/HCV-co-infection reflect fibrosis stage and degree of portal hypertension. PLoS One. 2014;9:e108544. https://doi.org/10.1371/journal.pone.0108544.CrossRefPubMedPubMedCentral

21.

Praktiknjo M, Lehmann J, Nielsen MJ, Schierwagen R, Uschner FE, Meyer C, Thomas D, Strassburg CP, Bendtsen F, Møller S, et al. Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. Hepatol Commun. 2018;2:211–22. https://doi.org/10.1002/hep4.1135.CrossRefPubMedPubMedCentral

22.

Lehmann J, Praktiknjo M, Nielsen MJ, Schierwagen R, Meyer C, Thomas D, Violi F, Strassburg CP, Bendtsen F, Møller S, et al. Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis. Liver Int. 2019;39:885–93. https://doi.org/10.1111/liv.14070.CrossRefPubMedPubMedCentral

23.

Jansen C, Reiberger T, Huang J, Eischeid H, Schierwagen R, Mandorfer M, Anadol E, Schwabl P, Schwarze-Zander C, Warnecke-Eberz U, et al. Circulating MiRNA-122 levels are associated with hepatic necroinflammation and portal hypertension in HIV/HCV coinfection. PLoS One. 2015;10:e0116768. https://doi.org/10.1371/journal.pone.0116768.CrossRefPubMedPubMedCentral

24.

Jansen C, Eischeid H, Goertzen J, Schierwagen R, Anadol E, Strassburg CP, Sauerbruch T, Odenthal M, Trebicka J. The role of MiRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS. PLoS One. 2014;9:e103779. https://doi.org/10.1371/journal.pone.0103779.CrossRefPubMedPubMedCentral

25.

Moreau R, Clària J, Aguilar F, Fenaille F, Lozano JJ, Junot C, Colsch B, Caraceni P, Trebicka J, Pavesi M, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol. 2020;72:688–701. https://doi.org/10.1016/j.jhep.2019.11.009.CrossRefPubMed

26.

Nicoară-Farcău O, Lozano JJ, Alonso C, Sidorova J, Villanueva C, Albillos A, Genescà J, Llop E, Calleja JL, Aracil C, et al. Metabolomics as a tool to predict the risk of decompensation or liver related death in patients with compensated cirrhosis. Hepatology. 2023. https://doi.org/10.1097/HEP.0000000000000316.CrossRefPubMed

27.

Weiss E, de la Peña-Ramirez C, Aguilar F, Lozano J-J, Sánchez-Garrido C, Sierra P, Martin PI-B, Diaz JM, Fenaille F, Castelli FA et al (2023) Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET). Gut gutjnl-2022–328708. https://doi.org/10.1136/gutjnl-2022-328708

28.

Seijo S, Lozano JJ, Alonso C, Reverter E, Miquel R, Abraldes JG, Martinez-Chantar ML, Garcia-Criado A, Berzigotti A, Castro A, et al. Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension. Am J Gastroenterol. 2013;108:926–32. https://doi.org/10.1038/ajg.2013.11.CrossRefPubMed

29.

Reverter E, Lozano JJ, Alonso C, Berzigotti A, Seijo S, Turon F, Baiges A, Martínez-Chantar ML, Mato JM, Martínez-Arranz I, et al. Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. Liver Int. 2019;39:705–13. https://doi.org/10.1111/liv.14042.CrossRefPubMed

30.

Elkrief L, Lazareth M, Chevret S, Paradis V, Magaz M, Blaise L, Rubbia-Brandt L, Moga L, Durand F, Payancé A, et al. Liver stiffness by transient elastography to detect porto-sinusoidal vascular liver disease with portal hypertension. Hepatology. 2021;74:364–78. https://doi.org/10.1002/hep.31688.CrossRefPubMed

31.

Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 Practice Guidance by the American Association for the study of liver diseases. Hepatology. 2017;65:310–35. https://doi.org/10.1002/hep.28906.CrossRefPubMed

32.

Berzigotti A, Tsochatzis E, Boursier J, Castera L, Cazzagon N, Friedrich-Rust M, Petta S, Thiele M. EASL Clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. J Hepatol. 2021;75:659–89. https://doi.org/10.1016/j.jhep.2021.05.025.CrossRef

33.

Salavrakos M, Piessevaux H, Komuta M, Lanthier N, Stärkel P. Fibroscan reliably rules out advanced liver fibrosis and significant portal hypertension in alcoholic patients. J Clin Gastroenterol. 2019;53:772–8. https://doi.org/10.1097/MCG.0000000000001119.CrossRefPubMed

34.

Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, Stefanescu H, Ma MM, Mandorfer M, Mergeay-Fabre M, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Off J Am College Gastroenterol | ACG. 2021;116:723. https://doi.org/10.14309/ajg.0000000000000994.CrossRef

35.

Semmler G, Lens S, Meyer EL, Baiges A, Alvardo-Tapias E, Llop E, Tellez L, Schwabl P, Mauro E, Escudé L, et al. Non-invasive tests for clinically significant portal hypertension after HCV cure. J Hepatol. 2022;77:1573–85. https://doi.org/10.1016/j.jhep.2022.08.025.CrossRefPubMed

36.

Jachs M, Hartl L, Bauer D, Simbrunner B, Stättermayer AF, Strassl R, Trauner M, Mandorfer M, Reiberger T. Long-term outcome of HBV-infected patients with clinically significant portal hypertension achieving viral suppression. J Pers Med. 2022;12:239. https://doi.org/10.3390/jpm12020239.CrossRefPubMedPubMedCentral

37.

Piecha F, Paech D, Sollors J, Seitz H-K, Rössle M, Rausch V, Mueller S. Rapid change of liver stiffness after variceal ligation and TIPS implantation. Am J Physiol Gastrointest Liver Physiol. 2018;314:G179–87. https://doi.org/10.1152/ajpgi.00239.2017.CrossRefPubMed

38.

Jansen C, Möller P, Meyer C, Kolbe CC, Bogs C, Pohlmann A, Schierwagen R, Praktiknjo M, Abdullah Z, Lehmann J, et al. Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality. Hepatology. 2018;67:1472–84. https://doi.org/10.1002/hep.29612.CrossRefPubMed

39.

Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M. Vienna Hepatic hemodynamic lab non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol. 2012;47:561–8. https://doi.org/10.1007/s00535-011-0517-4.CrossRefPubMed

40.

Zaghloul SG, Wahab EA, Seleem WM, Hanafy AS, Gomaa AF, Lakouz K, Amin AI. Impact of non-selective beta blockers on portal hypertension and hepatic elasticity in hepatitis C virus-related liver cirrhosis. Drug Discov Ther. 2019;13:108–13. https://doi.org/10.5582/ddt.2019.01009.CrossRefPubMed

41.

Brol MJ, Drebber U, Luetkens JA, Odenthal M, Trebicka J (2022) “The pathogenesis of hepatic fibrosis: basic facts and clinical challenges”—assessment of liver fibrosis: a narrative review. Dig Med Res 5. https://doi.org/10.21037/dmr-22-9

42.

Elkrief L, Rautou P-E, Ronot M, Lambert S, Dioguardi Burgio M, Francoz C, Plessier A, Durand F, Valla D, Lebrec D, et al. Prospective comparison of spleen and liver stiffness by using shear-wave and transient elastography for detection of portal hypertension in cirrhosis. Radiology. 2015;275:589–98. https://doi.org/10.1148/radiol.14141210.CrossRefPubMed

43.

Leung VY, Shen J, Wong VW, Abrigo J, Wong GL, Chim AM, Chu SH, Chan AW, Choi PC, Ahuja AT, et al. Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. Radiology. 2013;269:910–8. https://doi.org/10.1148/radiol.13130128.CrossRefPubMed

44.

Hristov B, Andonov V, Doykov D, Doykova K, Valova S, Nacheva-Georgieva E, Uchikov P, Kostov G, Doykov M, Tilkian E. Evaluation of liver stiffness measurement by means of 2D-SWE for the diagnosis of esophageal varices. Diagnostics (Basel). 2023;13:356. https://doi.org/10.3390/diagnostics13030356.CrossRefPubMed

45.

Dong B, Chen Y, Chen Y, Wang H, Lyu G. Diagnostic accuracy of liver stiffness on two-dimensional shear wave elastography for detecting clinically significant portal hypertension: a meta-analysis. Expert Rev Med Devices. 2023;20:141–9. https://doi.org/10.1080/17434440.2022.2077642.CrossRefPubMed

46.

Stefanescu H, Marasco G, Calès P, Fraquelli M, Rosselli M, Ganne-Carriè N, de Ledinghen V, Ravaioli F, Colecchia A, Rusu C, et al. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. Liver Int. 2020;40:175–85. https://doi.org/10.1111/liv.14228.CrossRefPubMed

47.

Dajti E, Ravaioli F, Marasco G, Alemanni LV, Colecchia L, Ferrarese A, Cusumano C, Gemini S, Vestito A, Renzulli M, et al. A combined Baveno VII and spleen stiffness algorithm to improve the noninvasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol. 2022;117:1825–33. https://doi.org/10.14309/ajg.0000000000001887.CrossRefPubMed

48.

Grgurevic I, Madir A, Trkulja V, Bozin T, Aralica G, Podrug K, Mikolaševic I, Tsochatzis E, O’Beirne J, Pinzani M. Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography. Eur J Clin Invest. 2022;52:e13750. https://doi.org/10.1111/eci.13750.CrossRefPubMed

49.

Moia R, Cittone MG, Boggione P, Manfredi GF, Favini C, Awikeh B, Pedrinelli AR, Mahmoud AM, Nicolosi M, Bellan M, et al. Stiffer spleen predicts higher bone marrow fibrosis and higher JAK2 allele burden in patients with myeloproliferative neoplasms. Front Oncol. 2021;11:777730. https://doi.org/10.3389/fonc.2021.777730.CrossRefPubMedPubMedCentral

50.

Zhao C-S, Wang N-F, You Y-M, Wang Y-J, Liu F, Cai F-F. The value of CD44+ mononuclear cells and spleen stiffness measurement in minimal residual disease in acute myeloid leukemia and its prognosis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29:715–9. https://doi.org/10.19746/j.cnki.issn.1009-2137.2021.03.010.CrossRefPubMed

51.

Marasco G, Dajti E, Ravaioli F, Alemanni LV, Capuano F, Gjini K, Colecchia L, Puppini G, Cusumano C, Renzulli M, et al. Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients. Hepatol Int. 2020;14:850–7. https://doi.org/10.1007/s12072-020-10062-w.CrossRefPubMed

52.

Buechter M, Manka P, Theysohn JM, Reinboldt M, Canbay A, Kahraman A. Spleen stiffness is positively correlated with HVPG and decreases significantly after TIPS implantation. Dig Liver Dis. 2018;50:54–60. https://doi.org/10.1016/j.dld.2017.09.138.CrossRefPubMed

53.

Wang C, Huang Y, Liu C, Liu F, Hu X, Kuang X, An W, Liu C, Liu Y, Liu S et al (2023) Diagnosis of clinically significant portal hypertension using CT- and MRI-based vascular model. Radiology 221648. https://doi.org/10.1148/radiol.221648

54.

Kennedy P, Stocker D, Carbonell G, Said D, Bane O, Hectors S, Abboud G, Cuevas J, Bolster BD, Friedman SL, et al. MR elastography outperforms shear wave elastography for the diagnosis of clinically significant portal hypertension. Eur Radiol. 2022;32:8339–49. https://doi.org/10.1007/s00330-022-08935-9.CrossRefPubMedPubMedCentral

55.

Danielsen KV, Hove JD, Nabilou P, Yin M, Chen J, Zhao M, Kallemose T, Teisner AS, Siebner HR, Ehman RL, et al. Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis. Liver Int. 2021;41:2149–58. https://doi.org/10.1111/liv.14981.CrossRefPubMedPubMedCentral

56.

Shi Y, Qi Y-F, Lan G-Y, Wu Q, Ma B, Zhang X-Y, Ji R-Y, Ma Y-J, Hong Y. Three-dimensional MR elastography depicts liver inflammation, fibrosis, and portal hypertension in chronic hepatitis B or C. Radiology. 2021;301:154–62. https://doi.org/10.1148/radiol.2021202804.CrossRefPubMed

57.

Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, et al. Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants. Gastroenterology. 2022;163:1079-1089.e5. https://doi.org/10.1053/j.gastro.2022.06.073.CrossRefPubMed

58.

Hai Y, Chong W, Eisenbrey JR, Forsberg F. Network meta-analysis: noninvasive imaging modalities for identifying clinically significant portal hypertension. Dig Dis Sci. 2022;67:3313–26. https://doi.org/10.1007/s10620-021-07168-y.CrossRefPubMed

59.

Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Scheiner B, Balcar L, Semmler G, Stättermayer AF, Pinter M, et al. The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension. Clin Gastroenterol Hepatol. 2022;S1542–3565(22):00957. https://doi.org/10.1016/j.cgh.2022.09.032.CrossRef

60.

Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, Procopet B, Bosch J, Genesca J, Berzigotti A, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the “Anticipate” study. Hepatology. 2016;64:2173–84. https://doi.org/10.1002/hep.28824.CrossRefPubMed

61.

Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, Stefanescu H, Ma MM, Mandorfer M, Mergeay-Fabre M, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease. Am J Gastroenterol. 2021;116:723–32. https://doi.org/10.14309/ajg.0000000000000994.CrossRefPubMed

62.

Jansen C, Bogs C, Verlinden W, Thiele M, Möller P, Görtzen J, Lehmann J, Vanwolleghem T, Vonghia L, Praktiknjo M, et al. Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: a prospective multicentre study. Liver Int. 2017;37:396–405. https://doi.org/10.1111/liv.13243.CrossRefPubMed

63.

Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, Chon CY, Choi EH, Han K-H. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885–94. https://doi.org/10.1002/hep.24121.CrossRefPubMed

64.

Wang J, Li J, Zhou Q, Zhang D, Bi Q, Wu Y, Huang W. Liver stiffness measurement predicted liver-related events and all-cause mortality: a systematic review and nonlinear dose–response meta-analysis. Hepatol Commun. 2018;2:467–76. https://doi.org/10.1002/hep4.1154.CrossRefPubMedPubMedCentral

Title: Non-invasive Assessment of Clinically Significant Portal Hypertension
Authors: Maximilian Joseph Brol
Juliana Gödiker
Frank Erhard Uschner
Michael Praktiknjo
Jonel Trebicka
Publication date: 13-07-2023
Publisher: Springer US
Keywords: Hypertension
Portal Hypertension
Portal Hypertension
Published in: Current Hepatology Reports / Issue 3/2023
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-023-00609-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2023

Chemoprevention in hepatocellular carcinoma

The Role of Micronutrients in Chronic Liver Disease

Current and Evolving Management of Chronic Hepatitis Delta Virus (HDV) Infection

Schistosomiasis: Hepatosplenic Disease and Portal Hypertensive Complications

Nodular Regenerative Hyperplasia

An Overview of the Therapeutic Development of Cholangiocarcinoma with Special Emphasis on Targeted and Biologic Therapies

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials